Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease

To the Editor: Patients with severe atopic dermatitis (AD), psoriasis (PSO), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD) may present as a therapeutic challenge to clinicians. Rarely, patients may present with 2 of these systemic inflammatory diseases. For these patients, dual biologic therapy may offer a solution. Although dual biologic therapy is infrequently described, published reports describe  promising results.1,2 Hesitation to prescribe dual therapy may exist due to concern of paradoxical upregulation of a separate axis after inhibition of intended axis, high costs, risk of infection, and lack of United States Food and Drug Adminstration approval.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: Research letter Source Type: research